Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2

被引:97
作者
Ohtsubo, T
Rovira, II
Starost, MF
Liu, CY
Finkel, T
机构
[1] NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA
[2] NHLBI, Transgen Core Facil, NIH, Bethesda, MD 20892 USA
[3] OD, Div Vet Resources, NIH, Bethesda, MD USA
关键词
kidney; cyclooxygenase;
D O I
10.1161/01.RES.0000149571.96304.36
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Xanthine oxidoreductase (XOR) is the enzyme responsible for the final step in purine degradation resulting in the generation of uric acid. Here we have generated mice deficient in XOR. As expected, these animals lack tissue XOR activity and have low to undetectable serum levels of uric acid. Although normal at birth, XOR-/- mice fail to thrive after 10 to 14 days, and most die within the first month. The cause of death appears to be a form of severe renal dysplasia, a phenotype that closely resembles what has been observed previously in cyclooxygenase-2 (COX-2) deficient mice. We further demonstrate that in the first month of life, a period in which the mouse kidney is undergoing rapid maturation and remodeling, wild-type mice exhibit an approximate to30-fold increase in renal XOR activity, with a corresponding induction of COX-2 expression. In contrast, during this same period, XOR-/- animals fail to augment renal COX-2 expression. Finally, we show that in vitro and in vivo, uric acid can stimulate basal COX-2 expression. These results demonstrate that XOR activity is an endogenous physiological regulator of COX-2 expression and thereby provide insight into previous epidemiological evidence linking elevated serum uric levels with systemic hypertension and increased mortality from cardiovascular diseases. In addition, these results suggest a novel molecular link between cellular injury and the inflammatory response.
引用
收藏
页码:1118 / 1124
页数:7
相关论文
共 42 条
[1]   Uric acid: role in cardiovascular disease and effects of losartan [J].
Alderman, M ;
Aiyer, KJV .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (03) :369-379
[2]   Uric acid and cardiovascular risk [J].
Alderman, MH .
CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (02) :126-130
[3]   URIC-ACID PROVIDES AN ANTIOXIDANT DEFENSE IN HUMANS AGAINST OXIDANT-CAUSED AND RADICAL-CAUSED AGING AND CANCER - A HYPOTHESIS [J].
AMES, BN ;
CATHCART, R ;
SCHWIERS, E ;
HOCHSTEIN, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (11) :6858-6862
[4]   Oxidases and oxygenases in regulation of vascular nitric oxide signaling and inflammatory responses [J].
Aslan, M ;
Freeman, BA .
IMMUNOLOGIC RESEARCH, 2002, 26 (1-3) :107-118
[5]  
BARBER SR, 2003, CIRCULATION, V108, P896
[6]   A SENSITIVE FLUOROMETRIC ASSAY FOR MEASURING XANTHINE DEHYDROGENASE AND OXIDASE IN TISSUES [J].
BECKMAN, JS ;
PARKS, DA ;
PEARSON, JD ;
MARSHALL, PA ;
FREEMAN, BA .
FREE RADICAL BIOLOGY AND MEDICINE, 1989, 6 (06) :607-615
[7]   RENAL-FUNCTION IN GOUT .4. ANALYSIS OF 524 GOUTY SUBJECTS INCLUDING LONG-TERM FOLLOW-UP STUDIES [J].
BERGER, L ;
YU, TF .
AMERICAN JOURNAL OF MEDICINE, 1975, 59 (05) :605-613
[8]   Xanthine oxicloreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications [J].
Berry, CE ;
Hare, JM .
JOURNAL OF PHYSIOLOGY-LONDON, 2004, 555 (03) :589-606
[9]  
Chinery R, 1998, CANCER RES, V58, P2323
[10]   URIC-ACID IRON-ION COMPLEXES - A NEW ASPECT OF THE ANTIOXIDANT FUNCTIONS OF URIC-ACID [J].
DAVIES, KJA ;
SEVANIAN, A ;
MUAKKASSAHKELLY, SF ;
HOCHSTEIN, P .
BIOCHEMICAL JOURNAL, 1986, 235 (03) :747-754